Pfizer is looking to enter the growing weight loss drug market, which it believes could be worth $90 billion, and wants to capture $10 billion of that segment. The company's experimental obesity pill danuglipron will release phase 2 trial data by the end of 2023, showing its effects in obese patients without diabetes. Eli Lilly's pill resulted in average weight losses of up to 14.7% in clinical trials. Novo Nordisk's oral semaglutide drug Rybelsus also showed average weight losses of 15.1% in trials. Analysts say for danuglipron to be competitive, it needs to show mid-teens percentage weight loss in its upcoming trials.
Category
🗞
NewsTranscript
00:00 It's Benzinga and here's what's on the block.
00:02 Pfizer is looking to enter the growing weight loss drug market,
00:05 which it believes could be worth 90 billion and wants to capture 10 billion of that segment.
00:10 The company's experimental obesity pill will release phase 2 trial data by the end of 2023,
00:16 showing its effects in obese patients without diabetes.
00:19 Eli Lilly's pill resulted in average weight losses of up to 14.7% in clinical trials.
00:25 Analysts say for Pfizer's weight loss drug to be competitive,
00:28 it needs to show mid-teens percentage of weight loss in the upcoming trials.
00:32 For all things money, visit Benzinga.com
00:34 [BLANK_AUDIO]